JCR Pharmaceuticals Co., Ltd.
JCRRF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $33,072 | $42,871 | $34,343 | $51,082 |
| % Growth | -22.9% | 24.8% | -32.8% | – |
| Cost of Goods Sold | $11,333 | $11,620 | $8,886 | $10,461 |
| Gross Profit | $21,738 | $31,251 | $25,457 | $40,621 |
| % Margin | 65.7% | 72.9% | 74.1% | 79.5% |
| R&D Expenses | $0 | $11,234 | $8,802 | $7,175 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $12,486 | $11,678 | $13,511 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $28,389 | $1 | $58 | $38 |
| Operating Expenses | $28,389 | $23,720 | $20,480 | $20,686 |
| Operating Income | -$6,650 | $7,532 | $4,975 | $19,933 |
| % Margin | -20.1% | 17.6% | 14.5% | 39% |
| Other Income/Exp. Net | $236 | -$288 | $437 | -$529 |
| Pre-Tax Income | -$6,414 | $7,244 | $5,412 | $19,404 |
| Tax Expense | -$1,718 | $1,707 | $1,625 | $4,886 |
| Net Income | -$4,759 | $5,507 | $3,772 | $14,507 |
| % Margin | -14.4% | 12.8% | 11% | 28.4% |
| EPS | -38.43 | 44.13 | 30.34 | 117.26 |
| % Growth | -187.1% | 45.5% | -74.1% | – |
| EPS Diluted | -38.43 | 43.92 | 30.22 | 116.79 |
| Weighted Avg Shares Out | 124 | 125 | 124 | 124 |
| Weighted Avg Shares Out Dil | 124 | 125 | 125 | 124 |
| Supplemental Information | – | – | – | – |
| Interest Income | $113 | $111 | $33 | $7 |
| Interest Expense | $155 | $86 | $44 | $45 |
| Depreciation & Amortization | $3,374 | $3,197 | $1,997 | $1,945 |
| EBITDA | -$2,885 | $10,528 | $7,453 | $21,394 |
| % Margin | -8.7% | 24.6% | 21.7% | 41.9% |